Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2020.
Events | Date* |
Cash position and activity update for Q4 2019 | February 4, 2020 |
2019 Annual Results | March 19, 2020 |
Cash position and activity update for Q1 2020 | April 23, 2020 |
Cash position and activity update for Q2 2020 | July 23, 2020 |
2020 Half Year Results | September 10, 2020 |
Cash position and activity update for Q3 2020 | October 22, 2020 |
* indicative dates subject to change |
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients. The biotech assets inherited from CERENIS Therapeutics constitute a rich portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005668/en/